|Bid||19.66 x 900|
|Ask||19.69 x 800|
|Day's Range||19.52 - 20.01|
|52 Week Range||13.92 - 28.18|
|Beta (5Y Monthly)||1.76|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Myriad Genetics' (MYGN) significant gross margin contraction and operating loss as a result of mounting cost pressure are concerning.
Statistically speaking, long term investing is a profitable endeavour. But along the way some stocks are going to...
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.